HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Quaden, C. Articles by Wallaert, B. Search for Related Content PubMed PubMed Citation Articles by Quaden, C. Articles by Wallaert, B.

Necrotising sarcoid granulomatosis: clinical, functional, endoscopical and radiographical evaluations

¹ Service de Pneumologie et d'Immuno-Allergologie, Hôpital Calmette, CHRU, Lille, France. ² Service de Pneumologie, Cliniques Universitaires UCL, Mont-Godine. ³ Service de Pneumologie, AZ-Saint Lucas, Gent, and ⁴ Service de Pneumologie, Université Zickenhuizen, Leuven, Belgium.

CORRESPONDENCE: B. Wallaert, Service de Pneumologie et d'Immuno-Allergologie, Hôpital Calmette, 1 rue Leclercq, 59037, Lille Cedex, France. Fax: 33 320445768. E-mail: bwallaert{at}chru-lille.fr

Keywords: Granulomatosis, necrotising, sarcoid-like

Received: March 2, 2005
Accepted July 14, 2005

	ABSTRACT

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 
Necrotising sarcoid granulomatosis (NSG) is a rare disease diagnosed on the basis of pathological features. The present study reports the characteristics of 14 cases of NSG.

The mean age at the appearance of first symptoms was 37 yrs and the mean delay between first symptoms and diagnosis was 1 yr. Extrarespiratory symptoms were more common (12 out of 14) than respiratory symptoms (eight out of 14). Seven patients had inflammatory syndrome. Bronchoalveolar lavage was performed in eight patients and found to be normal in three cases. Respiratory function was normal in 13 patients, but carbon monoxide diffusing capacity was slightly decreased in eight of the 11 patients tested. A computed tomography scan showed a solitary nodule in four out of 14 cases, bilateral nodules in three and infiltrates in seven.

One patient died from neurological complications despite treatment with corticosteroids and immunosuppressive drugs. Two cases of relapse were observed in patients initially treated with corticosteroids, and there were two cases of relapse after surgery. No relapse occurred in the five untreated patients. During the follow-up, lung cancer was detected at 26 months and 8 yrs, respectively, after NSG diagnosis in two patients.

In conclusion, no one treatment is associated with a better outcome than the others, although lung biopsy might be necessary in case of isolated nodule or cavitation. Greater vigilance is required during the follow-up.

Necrotising sarcoid granulomatosis (NSG) is a rare systemic disease, characterised by sarcoid-like granuloma, vasculitis and variable degrees of necrosis. Since its first description in 1973 by Liebow 1, several additional series and some case reports have been published. The aetiology and pathogenesis are both unknown. Common histological features are associated with a variety of clinical presentations in a heterogeneous population. For this reason, it is uncertain whether the histological characteristics represent a disease entity or a nonspecific reaction to various triggers. The aim of the present study is to describe the clinical course of patients diagnosed with NSG after histological examination of lung specimens.

	MATERIALS AND METHODS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 
Patient selection and study design
This multicentre study was conducted in five pulmonology departments at university hospitals (Lille and Roubaix, France; Mont-Godine, Gent and Leuven, Belgium) that treat patients with NSG. The centres were contacted by e-mail and asked to identify all patients diagnosed with NSG between January 1, 1989 and December 31, 2003. Patients were eligible if they presented pathological signs of NSG 1, namely numerous parenchymal sarcoid-like granulomas and noncaseating necrosis associated with granulomatous-, giant cell- or lymphocytic-type vasculitis involving both arteries and veins. Lung biopsies were all negative for bacteria, fungi and acid-fast bacilli (stains and cultures).

Patients attended the pulmonology departments at least every 6 months. A standard form was used to record the characteristics of the patients. The form comprised the following items: 1) epidemiological characteristics (age, sex, smoking history, occupation); 2) clinical and functional parameters, and results of a computed tomography (CT) scan at initial evaluation; and 3) follow-up evaluation under treatment, i.e. clinical and functional parameters and results of the CT scan.

Methods
Biological methods
All patients were tested for serum markers of inflammation. The erythrocyte sedimentation rate (normal: 7–15 mm in first hour) and C-reactive protein (CRP) concentration (normal: 0–6 mg·L^–1) were measured for all patients. Serum angiotensin-converting enzyme (ACE; normal: 10–55 IU·L^–1), antineutrophil cytoplasmic antibody (ANCA), antinuclear antibody and rheumatoid factor (as determined by laser nephelometry, where a titre of 40 IU was considered positive) were determined in all cases.

Pulmonary function tests
The pulmonary function tests consisted of standard spirometry and measurement of lung volumes with a body plethysmograph. The following parameters were recorded: forced expiratory volume in one second, forced vital capacity, functional residual capacity, residual volume and total lung capacity. The carbon monoxide diffusing capacity of the lung (D_L,CO) was determined by the single-breath method 2 and corrected for haemoglobin level. Data are expressed as absolute values and percentages of the predicted values 3.

Computed tomography
CT was always performed in the supine position. The CT scans were reviewed retrospectively and were independently interpreted by both a chest radiologist (M. Rémy-Jardin) and a chest physician (I. Tillie-Leblond). Agreement between the two readers was obtained by reaching a consensus regarding the nature of pulmonary abnormalities. The interobserver correlation coefficient was 0.86. Lesions seen on the CT scans were defined as solitary nodules, bilateral nodules, infiltrates, cavitation, hilar or mediastinal adenopathy and pleural thickening. Nodular lesions, characterised by soft tissue attenuation, consisted of micronodules (<5 mm) and larger nodules (5–10 mm or >10 mm). Cavitated nodules (with a central hole) were randomly distributed among nodules.

Bronchoscopy procedures
Endobronchial exploration was performed in each patient using a fibreoptic bronchoscope as previously described 4. The larynx was anaesthetised with a 2% Xylocaine® spray (AstraZeneca, Lund, Sweden). The degree of oxygen saturation was evaluated with a digital oxymeter. Macroscopic aspects of the tracheobronchial tree were recorded. Tracheobronchial secretions were sent for bacteriological and cytological examination. Patients also underwent bronchoalveolar lavage (BAL), bronchial biopsies and transbronchial biopsies (TBBs). BAL was performed according to standardised techniques 4 before biopsies were obtained to prevent alteration of cell values in the lavage fluid by blood leakage. When performed, TTBs were obtained by inserting forceps into a small peripheral bronchus. On average, five biopsies were obtained.

	RESULTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 
Clinical features
In total, 14 patients from five different pulmonary institutions were included in the study. Of these, 12 patients were followed by three centres. Two of these patients have been described previously 5, 6. Patients were followed-up for between 18 and 125 months (mean 56.6) at the time of final evaluation in December 2003.

Of the 14 patients, 10 were female and four were male (mean age: 42 yrs, range: 15–67) and all were Caucasian. The occupational and allergic history was noncontributive in all cases. Patients had previously had the following diseases: pulmonary tuberculosis (n = 2); type 2 diabetes (n = 2); thyroid disorder (n = 2); cancer of the oesophagus (n = 1); and idiopathic thrombocytopenia (n = 1). The clinical characteristics of the patients at the time of diagnosis are summarised in table 1. All patients except one were symptomatic at the time of the initial evaluation. Patient No. 11 was asymptomatic, but lung lesions were discovered by chance during a routine chest radiograph. The duration of symptoms prior to hospitalisation varied from several weeks to 1 yr. Extrarespiratory manifestations (86%) were more frequent than respiratory manifestations (57%). In 58% of cases, extrarespiratory manifestations first appeared at the same time as respiratory manifestations. In 29% of cases, extrarespiratory manifestations preceded pulmonary involvement by up to 2 yrs for cutaneous lesions in patient No. 14. Nonpulmonary manifestations followed respiratory manifestations in 17% of cases, with a mean delay of 1 yr.

Pulmonary examination was normal except in patient No. 12, where crackles were observed in lower lung fields, correlated with radiographical evidence of pulmonary infiltrates.

Inflammatory markers
The erythrocyte sedimentation rate (ESR) was elevated in nine out of the 14 cases. The ESR was >100 mm·h^–1 in two cases (patient Nos 1 and 7). Other markers of inflammation (CRP and fibrinogen) were within the normal range. The level of ACE was normal in all cases. All subjects were negative for rheumatoid factor and ANCAs. Patient No. 5, who had SS, was positive for antinuclear antibodies with a high titre (one out of 10,240) and a SS-A and SS-B characterisation.

Pulmonary function tests
The pulmonary function test results of the 14 study patients are shown in table 2.

CT findings
Table 3 shows the CT findings in the patients with NSG.

View larger version (162K): [in this window] [in a new window]   Fig. 1— Computed tomography scan of the lower lung zones showing bilateral airspace consolidation.

View larger version (125K): [in this window] [in a new window]   Fig. 2— Computed tomography scan at the level of the right bronchus intermedius showing small airway disease in the right upper lobe with areas of airspace consolidation in the lingula and the apical segment of the left lower lobe. The peripheral location of the axillary mass with irregular borders should be noted.

View larger version (144K): [in this window] [in a new window]   Fig. 3— Computed tomography scan at the level of the right bronchus intermedius, showing three nodular opacities with irregular borders, one located in the lingula and one located in the left lower lobe. The presence of areas of ground-glass attenuation in the posterior parts of both lower lobes corresponds to hypoventilated lung.

View larger version (149K): [in this window] [in a new window]   Fig. 4— Computed tomography scan at the level of the right bronchus intermedius, showing large areas of airspace consolidation in the right middle lobe, lingula and the apical segments of both lower lobes. The presence of cavitation within the right and left lower lobe masses should be noted.

View larger version (162K): [in this window] [in a new window]   Fig. 5— Histological stain showing coagulative necrosis and individual granulomas.

View larger version (164K): [in this window] [in a new window]   Fig. 6— Histological stain showing vascular involvement with extensive granulomatous infiltration of the media.

In this study, diagnosis of NSG was obtained by thoracotomy in all cases with 10 open-lung biopsies, two segmentectomies, one lobectomy and one wedge resection. This was the main inclusion criterion. Microscopic examination revealed a combination of granulomas (figs 5 and 6), necrosis (fig. 5) and angiitis in all specimens. The background lesion consisted of numerous parenchymal granulomas that were always sarcoid-like in nature. These isolated or confluent granulomas were hyalinised in some foci. Several kinds of vascular lesions were observed, as described by Liebow 1. Angiitis generally consisted of intramural granulomas or diffuse lymphocitic and plasma cell infiltration more or less confined to vessel walls. Giant cell arteritis was less frequent. The extent of coagulative necrosis varied considerably, from small punctate foci in angiocentric granulomas to large extravascular confluent zones. Pleural thickening was found in two cases.

Treatment and clinical course
The treatment and clinical course of the 14 patients are summarised in table 5. Mean follow-up from onset of disease to the end of the study was 54.6 months (range 18–114).

Five (36%) patients (patient Nos 1, 2, 5, 6 and 7) initially received corticosteroids after NSG diagnosis, with starting doses of between 0.5 and 1 mg·kg^–1·day^–1 of prednisone or prednisolone. Indications for treatment are summarised in table 5. The duration of steroid therapy ranged 1–68 months, with an average of 22.5 months. Steroids led to clearance of pulmonary condensations in 2–3 months in all five cases. Systemic symptoms (patient Nos 1, 5 and 7) and arthralgia resolved in <3 months under steroid therapy. Four patients responded favourably to steroids (patient Nos 1, 2, 5 and 7) and their treatment was progressively reduced. Patient No. 5 had a relapse when the prednisone dose was reduced from 30 to 20 mg·day^–1. The manifestations were the same as the first episode and responded to an increased steroid dose. This patient displayed steroid dependence, leading to prolonged treatment (68 months). Steroid therapy could be progressively reduced in patient Nos 1, 2 and 7 with no relapses. After discontinuation of treatment, a relapse occurred in patient No. 1. This patient presented the same clinical manifestations as during the first episode (cough and arthralgia), but different radiographic findings with bilateral nodules rather than irregular infiltrates. Again, these responded to steroid therapy. Eight years after NSG diagnosis, a right lower pulmonary mass (2.5 cm diameter) was detected in patient No. 2 and diagnosed as adenocarcinoma. In the 5^th patient (patient No. 6), who displayed cerebral manifestations, corticosteroids were ineffective and immunosuppressive agents were required. Despite treatment with cyclophosphamide (13 months) and azathioprine (76 months), the disease progression was unfavourable. Encephalic irradiation (35 Gy) failed to improve neurological degradation and the patient finally died 114 months after diagnosis.

The four patients (36%) with solitary nodules underwent surgical resection. Relapse occurred in two cases. Patient No. 8 presented another solitary nodule 31 months after initial surgery; this nodule spontaneously disappeared after a 1-yr observation period. In patient No. 10, the radiological presentation of the relapse was different from that of the first episode, with numerous bilateral nodules detected 2 yrs after initial diagnosis of NSG. These nodules partially regressed in 3 months.

On analysing the NSG relapses more closely, the following features were noted: 1) initial therapy (steroid therapy or surgical resection) in all cases; 2) mean interval between treatment and relapse of 32 months (range 24–43); 3) clinical and radiological presentation identical to first episode in two and one case out of three, respectively; 4) spontaneously favourable progression in two out of three cases and good response to steroid therapy in one out of three cases; and 5) no initial biological, radiological, functional or BAL profiles were predictive of relapse.

	DISCUSSION

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 
In 1973, Liebow 1 made the first reference to a disease characterised by sarcoid-like granulomata with vasculitis and necrosis when describing his classification of pulmonary angiitis and granulomatosis not produced by known infectious agents or associated with rheumatoid disease. He named this disease "necrotising sarcoid granulomatosis" and initiated the debate as to whether the disease represented necrotising angiitis with sarcoid reaction or sarcoidosis with necrosis of the granuloma and the vessels. NSG is diagnosed on the basis of pathological features and shares common histological and clinical patterns with sarcoidosis.

Since the original description, six additional series have been published 7–12, along with some case reports, giving a total of 100 cases. Extrarespiratory manifestations (mainly ophthalmological and neurological) 5, 7–9, 13–15 and a globally benign course 1, 7–9, 12, 16–20 were described. The aim of the present study was to reconsider the major aspects of NSG, using respiratory exploratory tests that have not always been extensively evaluated in previous series.

The sex and age distributions agree with previous series. Most patients were nonsmokers (nine out of 14). Clinical presentation was variable and nonspecific. Interestingly, extrarespiratory manifestations were found to be more common than respiratory ones. Systemic symptoms were more common than previously reported by Churg 9 and were prominent in most cases. Unlike subjects with Wegener's granulomatosis, patients with NSG have no upper airway disease, nephritis or systemic vasculitis 21. In the same way, uveitis or cutaneous lesions are rare in NSG, contrasting with their frequency in sarcoidosis.

Limited information is available in the literature about laboratory tests in NSG patients. It was noted that inflammatory markers were elevated in most patients. Interestingly, ACE concentrations were normal in all patients, whereas they are elevated in 60% of patients with active sarcoidosis 19, 20. Another biological parameter that could be useful for differential diagnosis was ANCA, as all tested patients in the study were negative for ANCA. ANCAs are clearly associated with systemic vasculitis (e.g. Wegener's syndrome), which is characterised by similar systemic symptoms and radiological patterns to NSG. Auto-antibodies (SS-A and SS-B) were detected in one patient with SS. None of the subjects in the study were positive for ACE or ANCA, which may be helpful when patients test positive for sarcoidosis or Wegener's syndrome.

Pulmonary function tests were normal in 13 out of the 14 patients. Only one patient had an obstructive–restrictive ventilatory defect with clinical evidence of coexisting chronic obstructive pulmonary disease. This contrasts with the results obtained by Chittock et al. 7, who reported ventilatory defects in five out of seven patients: four restrictive patterns and one mixed restrictive–obstructive pattern. Another difference with the observation made by Chittock et al. 7 is the frequency of diffusing capacity alteration. D_L,CO was decreased in eight out of 11 patients in the current study, whereas Chittock et al. 7 observed a defect in only two out of seven cases. CT scan results are rarely described in NSG patients, as most previous large series were published before this technique was routinely used. Three main parenchymal CT features are typically reported: diffuse infiltrates, bilateral nodules and solitary nodules 7, 21. The current results are in agreement with those of the study by Chittock et al. 7. There is some debate as to whether hilar or mediastinal adenopathies are a feature of NSG. In the earliest first reports, in which chest radiograph was the only form of radiographical exploration, lymph node enlargement was considered to be uncommon and thought to represent a means of distinguishing NSG from sarcoidosis 10. Chittock et al. 7 demonstrated that adenopathies were frequently found when CT scans were used (five out of seven patients). Bilateral hilar and/or mediastinal adenopathy were found in 36% of the study patients. Conversely, it was noted that pleural involvement was rare, whereas pleural thickening or effusion was seen on CT scans in six out of the seven patients reported by Chittock et al. 7. In the study by Chittock et al. 7, the main symptom of each patient was pleuritic chest pain. Due to the major differences in the radiological features typical of sarcoidosis and NSG, and due to the difficulty associated with distinguishing between infectious granulomatous processes, tumours and Wegener's syndrome on CT scans (even when a bronchoscopic biopsy reveals a granuloma or if biological tests and BAL findings are negative), a lung biopsy is usually performed 21. Although granulomas occur in a juxtalymphatic distribution which should mimic that seen in sarcoidosis, two important features of NSG distinguish it from sarcoidosis: the lower prevalence of mediastinal and hilar lymphadenopathy, and the cavitation seen in pulmonary lesions 21.

The value of BAL analysis when assessing lung involvement in NSG is unknown. The present study is the first to include the results of BAL explorations in NSG patients. It was noted that three of the eight patients tested had normal BAL findings. The others had variable and nonspecific features, associated with a predominance of lymphocytes, eosinophils or neutrophils. There was no alveolar haemorrhage.

As the histopathological features of NSG have been largely described previously 1, 8–10, 17, 22, the different techniques used to diagnose NSG were examined. In the current study, only large lung biopsies provided specimens that met these criteria. However, transbronchial needle aspiration (with or without ultrasound guidance) might be accurate in the diagnosis of benign lymphadenopathy including sarcoidosis. In addition, a needle biopsy of the parenchymal lesions might suggest the diagnosis of NSG, since Wegener's granuomatosis would be highly unlikely with a negative ANCA. Neoplastic lesions are unlikely in the absence of tumoural cells and a diagnosis of tuberculosis unlikely in the absence of organisms, since organisms are present in very high concentratiosn in the wall of a cavity or in an area of granulomatous necrosis. Therefore, it is likely that the diagnosis of NSG might be suspected and does not necessarily require thoracoscopic biopsy.

The data concerning the nature of the disease and its relationship to sarcoidosis are controversial. It is believed that clinical (frequency and severity of systemic symptoms), biological (normal ACE levels) and specific histopathological data are sufficient to show that NSG is a separate entity, slightly different from sarcoidosis. NSG appears to be intermediate between sarcoidosis and systemic necrotising vasculitides. Although NSG shares some pathological features with necrotising granulomatous angiitides, such as Wegener's granulomatosis or Churg-Strauss disease, it is not associated with ANCA, renal involvement or asthma. It is important to be able to distinguish NSG from these conditions because of differences in prognosis and response to treatment as demonstrated here.

The prognosis of NSG patients was described as being favourable in previous reports. In this study, only one patient had severe neurological complications leading to death. No other deaths related to central nervous system involvement have been reported in NSG patients. Two patients developed lung carcinoma 2 and 8 yrs after NSG diagnosis, respectively. NSG has previously been described in one patient with an oat-cell carcinoma of the lung 23. These two cases of lung cancer imply that a long observation period is required in patients with NSG and that the appearance of any new pulmonary condensations must be considered with great caution. In both cases, cancer was diagnosed on bronchial biopsy. In the remaining cases, treatment seemed to be associated with relapse and should be indicated only when symptoms are major.

In conclusion, given the relative benign nature of necrotising sarcoid granulomatosis, bronchoscopy should be performed to rule out cancer or infection, and lung biopsy is necessary in case of solitary nodule and/or cavitation (mainly when antineutrophil cytoplasmic antibodies are negative). Severe specific complications are rare in necrotising sarcoid granulomatosis, identified in only one case in this study. Contrasting with other studies, extrapulmonary manifestations can be found to be frequent in necrotising sarcoid granulomatosis. Relapses seem to be more frequent when treatment is proposed, and corticosteroids and other immunosuppressive drugs should be restricted to patients with major symptoms.

	ACKNOWLEDGEMENTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 
The authors would like to thank M-C. Coppin, M. Rémy-Jardin, F. Steenhouwer, C. Tulippe and L. Delaunois for their contribution and constructive comments.

	REFERENCES

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 

1. Liebow AA. The J. Burns Amberson Lecture pulmonary angiitis and granulomatosis. Am Rev Respir Dis 1973;108:1–18.[Web of Science][Medline] [Order article via Infotrieve]
2. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995;152:2185–2198.[Web of Science][Medline] [Order article via Infotrieve]
3. Quanjer PH. Standardized lung function testing. Report working party, standardization of lung function tests. Bull Eur Physiopathol Respir 1983;19:1–95.
4. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group. Eur Respir J 1989;2:561–585.[Web of Science][Medline] [Order article via Infotrieve]
5. Brevet F, Hachulla E, Courtin P, et al. Forme systémique de granulomatose nécrosante sarcoïdosique avec atteinte oculaire, pulmonaire et cérébrale [Systemic form of sarcoid-like necrotizing granulomatosis with ocular, pulmonary and cerebral involvement]. Rev Méd Interne 1993;14:243–248.[Web of Science][Medline] [Order article via Infotrieve]
6. Radenne F, Tillie-Leblond I, Maurage CA, et al. Syndrome de Gougerot-Sjögren et granulomatose nécrosante sarcoïdosique [Sjogren's syndrome and necrotizing sarcoid-like granulomatosis]. Rev Mal Respir 1999;16:554–557.[Web of Science][Medline] [Order article via Infotrieve]
7. Chittock DR, Joseph MG, Paterson NAM, et al. Necrotizing sarcoid granulomatosis with pleural involvement. Clinical and radiographic features. Chest 1994;106:672–676.[Abstract/Free Full Text]
8. Churg A, Carrington CB, Gupta R. Necrotizing sarcoid granulomatosis. Chest 1979;76:406–413.[Abstract/Free Full Text]
9. Churg A. Pulmonary angiitis and granulomatosis revisited. Hum Pathol 1983;14:868–883.[Web of Science][Medline] [Order article via Infotrieve]
10. Koss MN, Hochholzer L, Feigin DS, et al. Necrotizing sarcoid-like granulomatosis: clinical, pathologic and immunopathologic findings. Hum Pathol 1980;11:510–519.[Web of Science][Medline] [Order article via Infotrieve]
11. Sadoun D, Kambouchner M, Tazi A. Granulomatose nécrosante sarcoid-like [Necrotizing sarcoid granulomatosis. Apropos of 4 cases]. Ann Med Interne 1994;145:230–233.[Medline] [Order article via Infotrieve]
12. Saldana MJ. Necrotizing sarcoid granulomatosis: clinico-pathologic observations in 24 patients. Lab Invest 1978;38:364
13. Beach RC, Corrin B, Scopes JW, et al. Necrotizing sarcoid granulomatosis with neurological lesions in a child. J Pediatr 1980;97:950–953.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
14. Dykhuizen RS, Smith CC, Kennedy MM, et al. Necrotising sarcoid granulomatosis with extrapulmonary involvement. Eur Respir J 1997;10:245–247.[Abstract]
15. Singh N, Cole S, Krause PJ, et al. Necrotizing sarcoid granulomatosis with extrapulmonary involvement. Am Rev Respir Dis 1981;124:189–192.[Web of Science][Medline] [Order article via Infotrieve]
16. Gibbs AR, Jones Williams W. Necrotizing sarcoidal granulomatosis: a problem of identity. Sarcoidosis 1987;4:94–96.[Medline] [Order article via Infotrieve]
17. Niimi H, Hartman TE, Müller NL. Necrotizing sarcoid granulomatosis: computed tomography and pathologic findings. J Comput Assist Tomogr 1995;19:920–923.[Web of Science][Medline] [Order article via Infotrieve]
18. Spiteri MA, Gledhill A, Campbell D, et al. Necrotizing sarcoid granulomatosis. Br J Dis Chest 1987;81:70–75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
19. Lieberman J, Nosal A, Schlessner LA, et al. Serum angiotensin converting enzyme for diagnosis and therapeutic evaluation of sarcoidosis. Am Rev Respir Dis 1979;120:329–335.[Web of Science][Medline] [Order article via Infotrieve]
20. Rohatgi PK. Serum angiotensin converting enzyme in pulmonary disease. Lung 1982;160:287–301.[Web of Science][Medline] [Order article via Infotrieve]
21. Frazier AA, Rosado-de-Christenson ML, Galvin JR, et al. Pulmonary angiitis and granulomatosis: radiologic-pathologic correlation. Radiographics 1998;18:687–710.[Abstract]
22. Saldana MJ, Israel HL. Necrotizing sarcoid granulomatosis, benign lymphocytic angiitis and granulomatosis: do they exist? Sem Respir Med 1989;10:182–188.
23. Stephen JG, Braimbridge MV, Corrin B, et al. Necrotizing sarcoidal angiitis and granulomatosis of the lung. Thorax 1976;31:356–360.[Abstract/Free Full Text]

This article has been cited by other articles:

				S. Aliberti, M. Falleni, P. Tarsia, G. Vago, P. Zerbi, M. Barberis, V. Valenti, and F. Blasi A 13-year-old female with shortness of breath and pleuritic chest pain Eur. Respir. J., October 1, 2006; 28(4): 876 - 882. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Quaden, C. Articles by Wallaert, B. Search for Related Content PubMed PubMed Citation Articles by Quaden, C. Articles by Wallaert, B.